Table 8. Adjuvant Systemic Treatment Options for Women With Axillary
Node-Negative Breast Cancer
| Patient Group | Low Risk | Intermediate Risk | High Risk |
| Premenopausal, ER-positive or PR-positive | None or tamoxifen | Tamoxifen plus chemotherapy, tamoxifen alone, ovarian ablation, GnRH analoga | Chemotherapy plus tamoxifen, chemotherapy plus ablation or GnRH analog*, chemotherapy plus tamoxifen plus ovarian ablation or GnRH*, or ovarian ablation alone or with tamoxifen or GnRH alone or with tamoxifen |
| Premenopausal, ER-negative or PR-negative | — | — | Chemotherapy |
| Postmenopausal, ER-positive or PR-positive | None or upfront AI or tamoxifen followed by AI | Upfront AI or tamoxifen followed by AI +/- chemotherapy | Upfront AI or tamoxifen followed by AI +/- chemotherapy |
| Postmenopausal, ER-negative or PR-negative | — | — | Chemotherapy |
| AI = aromatase inhibitor; ER = estrogen receptor; GnRH = gonadotropin-releasing hormone; PR = progesterone receptor |
| a Note: This treatment option is under clinical evaluation. |
